ikena oncology (formerly kyn therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients, by understanding what drives their disease. we are advancing multiple development and discovery programs: an ep4 receptor antagonist; an ahr antagonist; a kynurenine-degrading enzyme; a discovery-stage program targeting the hippo signaling pathway; and a discovery-stage program against an undisclosed target.. in addition to raising capital from top tier investors orbimed advisors and atlas venture, we have entered into a global strategic collaboration with celgene on the ahr antagonist and kynase programs. “at ikena, we begin with the end in mind. we focus on subgroups of patients based on their biomarker profiles who will most benefit from our immunotherapy and tumor cell-targeted drug candidates, ensuring that we can bring the right drug to the right patient battling cancer.” mark manfredi, chief executi
Company profile
Ticker
IKNA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
IKNA stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
12 Mar 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
21 Feb 24
8-K
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
18 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Results of Operations and Financial Condition
9 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
11 Oct 23
DEF 14A
Definitive proxy
25 Sep 23
PRE 14A
Preliminary proxy
15 Sep 23
424B5
Prospectus supplement for primary offering
12 Sep 23
Latest ownership filings
SC 13G/A
FMR LLC
11 Mar 24
4
Caroline Germa
5 Mar 24
3
Caroline Germa
5 Mar 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Omega Fund VI, L.P.
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Jeffrey Ecsedy
2 Feb 24
4
Jotin Marango
2 Feb 24
4
Mark Manfredi
2 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 122.56 mm | 122.56 mm | 122.56 mm | 122.56 mm | 122.56 mm | 122.56 mm |
Cash burn (monthly) | (no burn) | (no burn) | 6.50 mm | 5.72 mm | 6.67 mm | 6.30 mm |
Cash used (since last report) | n/a | n/a | 44.75 mm | 39.36 mm | 45.88 mm | 43.35 mm |
Cash remaining | n/a | n/a | 77.80 mm | 83.19 mm | 76.67 mm | 79.20 mm |
Runway (months of cash) | n/a | n/a | 12.0 | 14.5 | 11.5 | 12.6 |
Institutional ownership, Q3 2023
88.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 62 |
Opened positions | 10 |
Closed positions | 3 |
Increased positions | 25 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 132.47 bn |
Total shares | 42.50 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Atlas Venture Life Science Advisors | 5.02 mm | $21.73 bn |
FMR | 4.46 mm | $19.30 bn |
Orbimed Advisors | 3.19 mm | $13.80 bn |
BVF | 3.17 mm | $13.72 bn |
Atlas Venture Fund X | 2.90 mm | $74.28 mm |
Biotechnology Value Fund L P | 2.50 mm | $0.00 |
Omega Fund Management | 2.25 mm | $9.74 bn |
Omega Fund VI | 2.25 mm | $0.00 |
CHI Advisors | 2.18 mm | $9.44 bn |
BMY Bristol-Myers Squibb | 2.13 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Caroline Germa | Stock Option Common Stock | Grant | Acquire A | No | No | 1.47 | 579,100 | 851.28 k | 579,100 |
1 Feb 24 | Jeffrey Ecsedy | Stock Option Common Stock | Grant | Acquire A | No | No | 1.36 | 100,000 | 136.00 k | 100,000 |
1 Feb 24 | Marango Jotin | Stock Option Common Stock | Grant | Acquire A | No | No | 1.36 | 181,000 | 246.16 k | 181,000 |
1 Feb 24 | Mark Manfredi | Stock Option Common Stock | Grant | Acquire A | No | No | 1.36 | 320,000 | 435.20 k | 320,000 |
News
The Analyst Landscape: 4 Takes On Ikena Oncology
19 Mar 24
HC Wainwright & Co. Reiterates Buy on Ikena Oncology, Maintains $11 Price Target
19 Mar 24
Ikena Oncology: Q4 Earnings Insights
12 Mar 24
HC Wainwright & Co. Maintains Buy on Ikena Oncology, Maintains $11 Price Target
12 Mar 24
Ikena Oncology Q4 EPS $(0.41) Beats $(0.43) Estimate, Sales $658.00K Miss $3.14M Estimate
12 Mar 24